Literature DB >> 3649921

Heparin promotes the inactivation of antithrombin by neutrophil elastase.

R E Jordan, J Kilpatrick, R M Nelson.   

Abstract

Heparin is an acceleratory cofactor for antithrombin, a circulating inhibitor of blood coagulation enzymes. The presence of heparin on blood vessel walls is believed to contribute to the nonthrombogenic properties of those surfaces. In apparent opposition to this function, heparin was found to greatly accelerate the in vitro inactivation of antithrombin by neutrophil elastase. Inactivation rates in solution were potentiated several hundredfold by specific heparin fractions with anticoagulant activity. Although the data suggest that a heparin-antithrombin complex is essential for the inactivation by elastase to occur, the enzyme itself interacts tightly with heparin. These results suggest a mechanism which, if operating in vivo, could lead to a localized neutralization of the anticoagulant function of heparin at the endothelial surface.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3649921     DOI: 10.1126/science.3649921

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  14 in total

1.  Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Authors:  Benjamin Richard; Richard Swanson; Sophia Schedin-Weiss; Ben Ramirez; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

2.  Probing serpin reactive-loop conformations by proteolytic cleavage.

Authors:  W S Chang; M R Wardell; D A Lomas; R W Carrell
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

3.  Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells.

Authors:  A D Snow; R P Bolender; T N Wight; A W Clowes
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

4.  Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI).

Authors:  Cristina Puy; Anh T P Ngo; Jiaqing Pang; Ravi S Keshari; Matthew W Hagen; Monica T Hinds; David Gailani; András Gruber; Florea Lupu; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-23       Impact factor: 8.311

5.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

6.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 7.  Coagulation inhibitor substitution during sepsis.

Authors:  F Fourrier; M Jourdain; A Tournois; C Caron; J Goudemand; C Chopin
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

8.  Mechanism of heparin acceleration of tissue inhibitor of metalloproteases-1 (TIMP-1) degradation by the human neutrophil elastase.

Authors:  Gabriel L C Nunes; Alyne Simões; Fábio H Dyszy; Claudio S Shida; Maria A Juliano; Luiz Juliano; Tarsis F Gesteira; Helena B Nader; Gillian Murphy; Alain F Chaffotte; Michel E Goldberg; Ivarne L S Tersariol; Paulo C Almeida
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

Review 9.  Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis.

Authors:  Steven M Opal; Charles T Esmon
Journal:  Crit Care       Date:  2002-12-20       Impact factor: 9.097

Review 10.  Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.

Authors:  Toshiaki Iba; Daizoh Saitoh
Journal:  J Intensive Care       Date:  2014-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.